Tirzepatide weight loss and the questions a scale leaves open
The amount of weight lost is one endpoint. What changed, what happened later, and what was not measured deserve space beside it.

Weight alone leaves out physical function
The direct weight-loss trial compared tirzepatide with semaglutide for 72 weeks in adults with obesity without type 2 diabetes. Lilly, which makes tirzepatide, funded this trial, called SURMOUNT-5. It was open-label, so participants knew which medicine they received.
Both groups lost weight on average. Tirzepatide's average reduction was larger. These are group results, rather than a forecast for you.
The household task pictured here is everyday context, not evidence of improved strength. Neither the photograph nor an average weight result establishes a change in physical function.
The scale result, side by side
Tirzepatide
In SURMOUNT-5, the estimated average weight loss with tirzepatide was 20.2% of starting weight at 72 weeks. That percentage describes body weight, not a fall in blood sugar.
Semaglutide
In the same trial, the estimated average weight loss with semaglutide was 13.7%. Both groups used weekly injections at maximum tolerated study doses. These are statistical estimates of average changes. The comparison doesn't cover every semaglutide product or tell us how each person will respond.
All weight loss isn't fat loss
Researchers used scans from 160 SURMOUNT-1 participants to estimate changes in fat and lean tissue. The participants were adults with obesity or overweight without diabetes. This was a post hoc analysis, looking back at data already collected. Across the pooled tirzepatide groups, about three quarters of the weight lost over 72 weeks was fat and one quarter was lean mass, on average. Those are shares of the weight lost, not of starting body weight.
Muscle is only part of lean mass; the scan counts other non-fat tissue too. It isn't a direct measure of strength. This study didn't compare body composition with semaglutide, so it can't tell us which medicine preserves more muscle.
The later chapter matters too
Tirzepatide
A tirzepatide withdrawal trial enrolled adults with obesity, or overweight with a weight-related condition, without diabetes. In SURMOUNT-4, 670 participants who completed a 36-week tirzepatide lead-in were randomly assigned to continue it or switch to placebo, an inactive comparison treatment, for another 52 weeks.
Those switched to placebo regained weight on average. Those continuing tirzepatide lost more on average. This result describes the people who reached randomization, not everyone who began treatment.
Semaglutide
A semaglutide follow-up tracked a subset of 327 STEP 1 participants, adults without diabetes, for a year after treatment and the lifestyle intervention stopped. Those previously assigned semaglutide regained a substantial share of their earlier weight loss on average.
That follow-up, the STEP 1 extension, had a different design. It can't supply a fair stopping-treatment ranking against SURMOUNT-4.
Follow-up does not write a stopping plan
Regain in a study doesn't write anyone's stopping plan. That's a conversation about the reason for treatment, the response and the person's wider health. A larger early weight change doesn't answer it.
Side effects stay in the picture
Both the tirzepatide and semaglutide labels list nausea, vomiting, diarrhea and constipation. Severe fluid loss can lead to kidney injury. Both also warn about pancreatitis (inflammation of the pancreas) and gallbladder problems.
Their strongest label warnings, called boxed warnings, concern thyroid C-cell tumors seen in rodents; human relevance is unknown. Reasons the labels rule out use include a personal or family history of medullary thyroid cancer, or having MEN 2, an inherited condition.
These brand-medicine studies also don't prove a compounded preparation will match their results. Compounded medicines aren't FDA-approved. The prescription notes explain why the exact product matters.
An average leaves individual variation visible
The estimated average combines different individual changes. It does not establish that everyone reached the same endpoint, or that a weight result predicts strength. The body-composition substudy adds another measurement, while leaving functional questions open. Its fat and lean-tissue findings cannot be turned into a personal forecast or a comparison it did not perform.